Discover how the interplay between AGEs-RAGE system and PD-1 inhibitors could revolutionize the treatment outcomes for advanced non-squamous non-small cell lung cancer patients lacking driver-gene mutations.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer.
Li et al., Cell Mol Biol (Noisy-le-grand) 2023
DOI: 10.14715/cmb/2023.69.14.25
This study investigates the effectiveness of PD-1 inhibitors in treating advanced non-squamous non-small cell lung cancer (nsNSCLC) without driver-gene mutations and examines the role of the AGEs-RAGE system in this context. A total of 130 nsNSCLC patients were divided into two groups: the control group (61 patients) received pemetrexed plus carboplatin, while the research group (69 patients) received PD-1 inhibitors in addition to pemetrexed and carboplatin.
Key findings:
– The research group had a higher disease control rate (DCR) than the control group (P<0.05).
– Median progression-free survival (PFS) was longer in the research group (P<0.05).
– After treatment, the research group showed higher levels of CD3+ and CD4+ T cells, and lower levels of CD8+ T cells, AGEs, and RAGE compared to the control group (P<0.05).
– The therapeutic effect of PD-1 inhibitors was inversely related to AGEs and RAGE levels (P<0.05).
Importance: The study suggests that PD-1 inhibitors can be effective for treating advanced nsNSCLC without driver-gene mutations. Additionally, the AGEs-RAGE system may be a useful biomarker for predicting treatment outcomes with PD-1 inhibitors, potentially guiding more effective therapies for nsNSCLC patients.